Benefits
IBS-D and post-infectious IBS — strongest gut evidence
RCT (Gut, n=106 post-infectious IBS-D) — 15 g/day (5g three times daily) × 8 weeks. 79.6% of glutamine group achieved >50-point IBS-SSS reduction vs 5.8% placebo. Striking effect size compared to most IBS interventions. Most relevant for IBS-D specifically (especially post-infectious onset), not all IBS subtypes. Mechanism: glutamine fuels enterocyte renewal and tight-junction protein synthesis.
Intestinal permeability — dose-dependent
meta-analysis (Amino Acids 56:60) of clinical trials on gut permeability: overall NO significant effect at typical supplemental doses. Subgroup analysis: significant reduction with doses >30 g/day for durations <2 weeks. Major implication: standard 5-10 g/day 'leaky gut' protocols are below the effective dose threshold. Pugh 2017 athletes: even low doses helpful for exercise-induced permeability; matrix matters.
Sickle cell disease — FDA-approved indication
FDA approved L-glutamine (Endari®, Emmaus Medical) for sickle cell disease in 2017 based on phase 3 trial in 230 patients ≥5 years old. 0.3 g/kg twice daily reduced sickle cell crises by 25% (3.0 vs 4.0 events/year), hospitalizations by 33% (2.0 vs 3.0), and shortened hospitalizations. Mechanism: glutamine supports NAD+/NADH redox balance in red blood cells, reducing oxidative damage and sickling triggers.
Critical illness — REDOXS shifted the field
REDOXS trial (NEJM 368:1489) — 1,223 critically ill patients: high-dose glutamine + antioxidants showed INCREASED 28-day mortality (32.4% vs 27.2%, p=0.05). Reset prior enthusiasm for routine glutamine in ICU. European/American guidelines now caution against parenteral glutamine in shock/multi-organ failure. Specific scenarios (burns, short bowel syndrome) retain enteral glutamine indications.
Athletic recovery — overrated in marketing
Despite heavy marketing for muscle recovery, RCT evidence is weak. Multiple meta-analyses find inconsistent effects on muscle soreness, performance, or recovery markers in healthy athletes. Glutamine stores in muscle are typically maintained adequately by dietary protein. More plausible benefit: protection against exercise-induced gut permeability — particularly relevant for endurance athletes.
Chemotherapy mucositis and short bowel syndrome
Established clinical applications in oncology supportive care. Glutamine reduces severity of chemotherapy-induced oral mucositis and improves enterocyte turnover after intestinal resection. Used in specialized rehydration solutions for short bowel syndrome where its dual role (sodium cotransport substrate + enterocyte fuel) is uniquely valuable. Tumor cell uptake concerns (theoretical 'feeding cancer') generally not supported by clinical data.
Wound healing and surgical recovery
Multiple trials in burn patients and major surgical populations show glutamine supplementation accelerates wound healing, supports collagen synthesis, and reduces infection rates. Enteral glutamine has stronger evidence than parenteral in non-critical-illness contexts. Reasonable component of nutrition support in surgical and burn care; not validated for cosmetic wound healing in healthy adults.
Sodium cotransport and oral rehydration
Glutamine functions as a sodium cotransport substrate in the small intestine, supporting fluid absorption parallel to glucose-mediated SGLT1. Glutamine-based ORS produced sodium/water absorption comparable to WHO standard in cholera-toxin animal models. Pediatric diarrhea trials vs WHO-ORS have been mixed. Specialized application in short bowel syndrome rehydration.
Mechanism of action
Primary fuel for enterocytes
Glutamine supplies 60-70% of energy for small intestinal epithelial cells (enterocytes), which turn over every 3-5 days. It's the single most important nutrient for maintaining intestinal barrier integrity. Enterocytes preferentially metabolize glutamine over glucose. This is the molecular basis for the gut-related clinical applications.
Conditionally essential under stress
Endogenous glutamine synthesis (primarily skeletal muscle) typically meets demand. During catabolic stress — sepsis, burns, major surgery, prolonged intense exercise — demand exceeds production, depleting muscle and plasma glutamine pools. Supplementation rationale strongest in these stress states; less clear in healthy adults at rest.
Immune cell substrate
Lymphocytes, macrophages, and neutrophils require glutamine at rates similar to glucose. Glutamine availability affects T-cell proliferation, cytokine production, and phagocytic function. Mechanism behind clinical utility in critical illness and post-surgical infection prevention.
Nitrogen carrier and acid-base balance
Glutamine is the major non-toxic transport form for nitrogen between tissues. Renal glutamine catabolism produces ammonia for excretion, contributing to acid-base homeostasis. Plays key role in interorgan amino acid metabolism.
Sickle cell redox protection
Glutamine supports NAD+/NADH balance in red blood cells, reducing oxidative damage that triggers sickling. Mechanism behind FDA-approved Endari® indication. Sickle cells have reduced glutamine uptake capacity, making supraphysiologic doses necessary for therapeutic effect.
Clinical trials
Double-blind placebo-controlled RCT in 106 patients with post-infectious diarrhea-predominant IBS. L-glutamine 5 g three times daily (15 g/day) × 8 weeks vs placebo. 79.6% of glutamine group achieved >50-point reduction in IBS-SSS vs 5.8% on placebo. Striking effect size; most rigorous evidence for glutamine in functional GI disease. Population specificity: post-infectious IBS-D only, not generalizable to all IBS.
Systematic review and meta-analysis of clinical trials on glutamine and intestinal permeability. Overall: NO significant effect at typical doses (WMD -0.00, 95% CI -0.04 to 0.03). Subgroup analysis: significant reduction with doses >30 g/day for durations <2 weeks. Critical implication: standard 5-10 g/day 'leaky gut' recommendations are below the effective dose threshold.
Phase 3 RCT in 230 patients ≥5 years old with sickle cell anemia or sickle β0-thalassemia. L-glutamine 0.3 g/kg twice daily × 48 weeks vs placebo. Median sickle cell crises: 3.0 vs 4.0 (25% reduction). Hospitalizations: 2.0 vs 3.0 (33% reduction). FDA approved as Endari® in 2017 for sickle cell disease in patients ≥5 years.
Multicenter RCT in 1,223 mechanically ventilated critically ill adults. Glutamine + antioxidants vs placebo. INCREASED 28-day mortality with glutamine (32.4% vs 27.2%, p=0.05). Trend toward increased in-hospital and 6-month mortality. Reset of routine glutamine use in ICU; specific subpopulations (burns, short bowel) retain enteral glutamine indications.
Dose-response study in athletes evaluating glutamine vs exercise-induced intestinal permeability. Even low doses (0.25 g/kg, ~17 g for 70kg adult) attenuated permeability vs placebo. Higher doses produced greater barrier protection. Relevant for endurance athletes with gut symptoms; provides physiologically plausible mechanism for glutamine's perceived recovery benefits beyond direct muscle effects.